Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 open-label APX001 study in invasive mold infections
MOH_2019-10-24_007451Phase 2Completed
- Sponsor
- Amplyx Pharmaceuticals
- Start
- Oct 2019
- Modality
- Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of fosmanogepix in Invasive Mold Infections (IMIs), aspergillosis and invasive mycoses, sponsored by Amplyx Pharmaceuticals. Started Oct 2019; status: completed.
02
Drugs
fosmanogepix
03
Conditions
Invasive Mold Infections (IMIs)aspergillosisinvasive mycoses
Beyond the preview
Go deeper on MOH_2019-10-24_007451.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2019-10-24_007451.